MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis

Objective. To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA.Methods. Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology 2020-09, Vol.59 (9), p.2392-2401
Hauptverfasser: Barendregt, A.M., Veldkamp, S.R., Muller, P.C.E.H., Geer, A. van de, Aarts, C., Gulik, E.C. van, Schilham, M.W., Kessel, C., Keizer, M.P., Hemke, R., Rashid, A.N.S., Dolman, K.M., Schonenberg-Meinema, D., Cate, R. ten, Berg, J.M. van den, Maas, M., Kuijpers, T.W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective. To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA.Methods. Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and 81 (II) patients with new-onset, DMARD-naive arthritis and compared patients who responded to treatment (defined as fulfilling >= adjusted ACRpedi50 response and/or inactive disease) with non-responders (defined as fulfilling < adjusted ACRpedi50 response and/or active disease) at 6 and 12 months. Secondly, we compared biomarker levels of 54 (I) and 34 (II) patients with clinically inactive disease who did or did not suffer from a flare of arthritis after 6 or 12 months. Receiver operating characteristic analyses were carried out to study the predictive value of MRP8/14 and NE for treatment response and flare.Results. For both cohorts, baseline MRP8/14 and NE levels for patients who did or did not respond to treatment were not different. Also, MRP8/14 and NE levels were not different in patients who did or did not flare. Receiver operating characteristic analysis of MRP8/14 and NE demonstrated areas under the curve
DOI:10.1093/rheumatology/kez590